Trial Information - Phase I
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Protocol ID: RGX-104-001
Sponsor: Inspirna, Inc
Status: PENDING OPEN
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
